Milzinfarkt bei Polycythaemia vera

Milzinfarkt bei Polycythaemia vera


Polycythaemia vera RadiopaediaCC-by-nc-sa 3.0de

Polycythemia vera (older term: polycythemia rubra vera) is a myeloproliferative neoplasm that results in an excess of red blood cells in the bloodstream.

Epidemiology

The estimated prevalence is around 2-3 per 10,000 people. It typically presents in older individuals. There may be a slightly greater male predilection.

Pathology

Markers

JAK2 mutations (particularly the V617F mutation) can be found in more than 95% of people with polycythemia vera.

Diagnostic criteria

Major WHO criteria are as follows:

  • Hemoglobin >16.5 g/dL in men and >16 g/dL in women, or hematocrit >49% in men and >48% in women, or red cell mass >25% above mean normal predicted value

  • Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size)

  • Presence of JAK2V617F or JAK2 exon 12 mutation

  • The minor WHO criterion is as follows:

    • Serum erythropoietin level below the reference range for normal

    Radiographic features

    Radiographic manifestations are varied and non-specific and can affect a number of systems, including:

    Complications

    Treatment and prognosis

    The overall prognosis can be variable with a wide natural course amongst individuals. Treatment options include venesection, myelosuppressive medications, interferon, and aspirin.

    Anagrelide is used when secondary thrombocythemia is an issue. Oral radiophosphorus (32-P) is now avoided in 'benign' myeloproliferative diseases due to the risk of inducing acute myeloid leukemia .

    See also


    Milzinfarkt RadiopaediaCC-by-nc-sa 3.0de

    Splenic infarction is a result of ischemia to the spleen, and in many cases requires no treatment. However, identification of the cause of infarction is essential.

    Epidemiology

    Splenic infarcts can occur due to a number of processes, involving either arterial supply, the spleen itself or the venous drainage. As such there is no one affected demographic; rather the demographics will vary with the underlying cause.

    Clinical presentation

    Patients with a splenic infarction may present with left upper quadrant pain. Some may have constitutional symptoms such as fevers and chills while others may even have diffuse abdominal pain. Due to the location of the spleen, tucked under the left hemidiaphragm, referred pain to the left shoulder is also a feature .

    It should be noted that ~40% (range 30-50%) of patients with splenic infarction are asymptomatic .

    Pathology

    Etiology

    The majority of patients with splenic infarcts have one of the following two etiologies:

    Other etiological factors include :

    Radiographic features

    The appearance of splenic infarction depends on the timing of imaging and the size of the infarct. Although once the infarct has become established, both ultrasound and CT are sensitive to the diagnosis, in the hyperacute setting CT with contrast is the modality of choice if the diagnosis is suspected .

    Morphologically the typical infarct is of a pyramidal wedge of affected splenic tissue with the apex pointing towards the hilum, and the base on the splenic capsule.

    As the infarct matures, the wedge of infarcted tissue can undergo one of three processes which will dictate imaging features:

  • resolution: no imaging findings
  • contraction/scarring
  • liquefaction
  • Ultrasound

    Typically infarcts are hypoechoic compared to the rest of the spleen, although acutely they can be isoechoic and hard to identify. Sonographic features of acute splenic infarcts regarding shape can vary and include :

    • wedge-shaped (classic)
    • round 
    • irregularly
    • smooth (uncommon)

    During contrast-enhanced ultrasound, the infarcted area remains hypointense throughout all phases of the study .

    As the infarct matures, if it undergoes contraction and scarring it will appear as a hyperechoic region with retraction of the capsule . If liquefaction occurs, the area may be rounded and anechoic (splenic pseudocyst).

    CT

    CT is often considered the imaging investigation of choice, ideally performed during the portal venous phase, to avoid confusing heterogeneous enhancement normally seen during arterial phase. Imaging features may vary with the stage of the infarct.

    In the hyperacute phase, CT may show areas of mottled increased attenuation, representing areas of a hemorrhagic infarction.

    There are various classical and non-classical patterns of established splenic infarcts on CT, which include :

    • peripheral, wedge-shaped hypoenhancing region: typical
    • multiple infarcts appear as hypodense non-enhancing lesions, with normal intervening enhancing splenic tissue.
    • global splenic infarction, entire spleen is hypoenhancing, e.g. in splenic torsion
    • infarction of a splenunculus

    In the chronic phase, infarcts may disappear completely, but more commonly, they may reveal progressive volume loss caused by fibrotic contraction of the infarct, with hypertrophy of the surrounding normal spleen . Alternatively, if the infarct liquefies, a cystic lesion may be left with fluid density centrally .

    Treatment and prognosis

    Initial management usually consists of hydration, analgesics, and frequent monitoring, with the resolution of symptoms in 7-14 days. Splenectomy was performed for persistent symptoms or complications.

    Complications

    Some complications are encountered, more frequently in patients with an embolic etiology. These include:

    Differential diagnosis

    Often, when imaging appearances are typical, there is little differential diagnosis. When less typical, or when imaging is suboptimal, alternative diagnoses should be entertained, including :

    See also